Nykredit A/S’s Viking Therapeutics VKTX Stock Holding History

Nykredit A/S’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Buy	+4,217	New	+$136K	﹤0.01%	1117

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nykredit A/S's VKTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 4,217 shares worth $165K. The stake represents ﹤0.01% of the portfolio and ranks #1117 among its holdings.

316 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Nykredit A/S held 4,217 shares of Viking Therapeutics worth $165K as of Q2 2026.
Viking Therapeutics was a new Nykredit A/S position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1117 holding.
316 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.